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The muscarinic acetylcholine receptor (mAChR) is a G-protein 
coupled receptor which has been implicated in the regulation of higher 
cognitive fbnctions such as learning and memory.( 1) In addition, alterations 
in mAChR densities and loss of choline acetyltransferase activity are well- 
known trademarks of Alzheimer's disease.( 1,2,3) These observations have 
led to the hypothesis that enhancement of the cholinergic system using 
mAChR agonists or acetylcholinesterase (AChE) inhibitors can lead to 
amelioration of AD symptoms. Although numerous approaches to 
bolstering the ,cholinergic system have been developed (AChE inhibitors, 
acetylcholine-releasing agents, and cholinergic agonists), relatively little is 
known on how these drugs affect receptor occupancy by acetylcholine 
(ACh). The in vivo imaging of mAChR. availability, using PET,. might 
provide a method for evaluating new or existing pharmaceutical approaches 
to  enhancing the cholinergic system, provided a suitable 
radiopharmaceutical with demonstrated sensitivity to ACh levels were to be 
available. 
Towards this goal, we had previously re orted the synthesis, "F- 
labeling, and in vitro Ki values of of N-(2-[ F]fluoroethyl)-4-piperidyl 
benzilate (l), a moderate affinity (Ki = 1.7 nM), non-subtype selective 
antagonist. This compound was shown to have good uptake in muscarinic 
receptor-rich regions of the rodent brain, was sensitive to changes in 
endogenous ACh levels, and displayed excellent bolus pharmacokinetics in 
primates.(4,5) However, difficulties were encountered when applying this 
compound in a bolus plus infbsion protocol in primates. As a result, we 
turned our efforts towards the synthesis and biological evaluation of (R)-N- 
["C]methyl-3-pyrrolidyl benzilate (2a, Ki = 0.72 nM) as a candidate for an 
ACh-sensitive PET ligand for mAChRs. 
Compound 2a was prepared by reacting the precursor (2b) with 
["Clmethyl triflate in d'imethylacetamide at room temperature. ' After 
diluting with cyclohexane, the reaction contents are loaded onto a short 
. 
I! 
J. Labelled Cpd Radiopharm 44, Suppl. 1 (2001) 
Symposium Abstracts S2.5 
alumina column, and the excess dimethylacetamide is removed by washing 
with additional cyclohexane. The desired compound is then eluted with a 
MeOWCH2CI2 solution, followed by evaporation of the solvent, and 
reformulation in ethanol/saline. The entirely automated reaction sequence 
takes 20 minutes following EOB. Radiochemical purities are typically 
>95%, with no evidence of the biologically active 2b. Radiochemical yields 
are typically 350-400 mCi for a 25 min, 20 vamp beam. 
**p*+ Ph-pt0...C=.-. OH 
2a: R="CH3 
2b: R = H  
Initial studies have shown that 2a has excellent retention in the 
mAChR-rich regions of  the rodent brain. Moreover, the 
striatudcerebellum, cortex/cerebellum, and striatudcortex ratios for 2a 
exceed those of 1 for both the mouse and rat. Bolus studies in monkeys 
showed that 2a had pharmacokinetics superior to those of other known "C- 
labeled muscarinic ligands, such as ["CITRB and ["CINMPB. In contrast 
to 1, bolus plus inhsion experiments with 2a in monkeys have shown that it 
is possible to achieve cortical equilibrium within short time frames. We are 
currently investigating the sensitivity of 2a to phenserine-induced ACh 
changes. 
In conclusion, we have synthesized a novel carbon-1 1 labeled 
muscarinic antagonist for use as an ACh-sensitive ligand for the mAChR 
The radiochemical synthesis of 2a is remarkably easy and 
reproducible, requires no HPLC purification, and provides excellent 
radiochemical yields within a short overall reaction time. The biological 
data for 2a suggests that this compound is superior to many other known 
muscarinic PET radioligands in terms of its retention in mAChR-rich 
regions and pharmacokinetics in rodents and primates. 
'system. 
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